Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
112.6 GBX | +1.30% | -1.66% | -45.87% |
May. 03 | Jefferies cuts AJ Bell; Deutsche likes ConvaTec | AN |
Apr. 22 | Jefferies raises B&M to 'hold' | AN |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Thanks to a sound financial situation, the firm has significant leeway for investment.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- With an enterprise value anticipated at 3.13 times the sales for the current fiscal year, the company turns out to be overvalued.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- For the last four months, the sales outlook for the coming years has been revised downwards. No recovery of the group's activities is yet foreseen.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
- The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Advanced Medical Equipment & Technology
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-45.87% | 1.21B | C | ||
+12.06% | 227B | B | ||
+12.07% | 192B | B- | ||
+13.88% | 136B | B- | ||
+27.12% | 108B | A- | ||
+0.30% | 64.07B | A- | ||
+13.39% | 52.1B | B+ | ||
+6.74% | 51.87B | B+ | ||
+8.81% | 44.33B | A | ||
+4.14% | 36.75B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- ONT Stock
- Ratings Oxford Nanopore Technologies plc